Faricimab (Vabysmo ®) for neovascular (wet) age-related macular degeneration. HTA ID: 22060

Assessment Status Awaiting full HTA submission from Applicant
HTA ID 22060
Drug Faricimab
Brand Vabysmo ®
Indication For the treatment of adult patients with neovascular (wet) age-related macular degeneration.
Assessment Process
Rapid review commissioned 29/08/2022
Rapid review completed 04/10/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of faricimab compared with the current standard of care.*
Full pharmacoeconomic assessment commissioned by HSE 25/10/2022
Pre-submission consultation with Applicant 03/10/2023

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.